1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > 2016-2020 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400.

VPGMarketResearch.com's new report is a study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

U.S. Market Overview

- Five-year test volume and sales projections.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

- Estimated universe of laboratories performing cancer diagnostic testing.

- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test.

- Five-year test volume and sales forecasts for major tumor markers by market segment, including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

   - Abbott
   - AdnaGen/Alere
   - Agilent Technologies
   - Applied Gene Technologies
   - Arca Biopharma
   - Beckman Coulter/Danaher
   - Becton Dickinson
   - Biomedical Diagnostics
   - bioMerieux
   - Bio-Rad
   - CellSearch
   - Cepheid
   - Correlogic Systems/Vermillion
   - Decode Genetics
   - Diadexus
   - Diagnocure
   - DiaSorin
   - Eiken Chemical
   - Elitech Group
   - Enterix
   - Enzo Biochem
   - Epigenomics
   - Exact Sciences
   - Fujirebio
   - Guided Therapeutics
   - Hologic/Gen-Probe
   - Kreatech/Leica
   - Kyowa Medex
   - Mackay Life Sciences
   - Myriad Genetics
   - OncoLab
   - Ortho-Clinical Diagnostics
   - Panacea Pharmaceuticals
   - Polartechnics
   - Polymedco
   - PreMD
   - Qiagen
   - Quest Diagnostics
   - Radient Pharmaceuticals
   - Roche
   - Scienion
   - Sequenom
   - Siemens Healthcare
   - Takara Bio
   - Targeted Diagnostics & Therapeutics
   - Thermo Fisher
   - Tosoh
   - Veridex
   - Wako Pure Chemicals
   - Wallac/PE
   - Zilla

Contains 620 pages and 103 tables


Table Of Contents

2016-2020 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
New Frontiers in the US Cancer Diagnostics Market:
Business Challenges, Emerging Technologies, Competitive Landscape
Table of Contents

I. Introduction
II. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Table of Contents

VI. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
Table of Contents
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
Table of Contents

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
Table of Contents
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
Table of Contents
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
c. Sequencing
d. Microarrays/Biochips
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
Table of Contents
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
VII. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers' Sales
And Market Shares
Table of Contents
VIII. Competitive Profiles
- Abbott
- AdnaGen
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Epigenomics
- Enterix
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
Table of Contents
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

IX. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications



List of Tables

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
Major Companies Developing or Marketing
HCG Tests


List of Tables


Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis


List of Tables

Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast
By Market Segment
U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates
Per 100,000 Population
U.S., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests
By Annual Test Volume
U.S., Physician Office Laboratories
Performing Tumor Marker Tests
By Practice Size
U.S., Total Tumor Marker Test Volume
Forecast by Market Segment

U.S., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast
U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test


List of Tables
U.S., Total Tumor Marker Sales
Forecast by Market Segment
U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment

U.S., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment


List of Tables
U.S., CEA Test Volume and Diagnostics
Sales by Market Segment
U.S., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Colon-specific Antigen Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Cytokeratins Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Estrogen Receptor Test Volume
And Diagnostics Sales Forecast by Market Segment

U.S., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Interferons Test Volume
And Diagnostics Sales Forecast by Market
Segment
U.S., Interleukins Test Volume
And Diagnostics Sales Forecast
by Market Segment
U.S., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment


List of Tables
U.S., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Occult Blood Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment


List of Tables
U.S., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Total Tumor Marker Sales
By Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales
by Major Supplier
U.S., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier


List of Tables
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market
Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review,  Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.